Portfolio Lab

Vertex Pharmaceuticals Inc / Ma

  • Stock
  • Ticker VRTX
  • ISIN US92532F1003
  • Nasdaq

Health care · Pharmaceuticals · USA

$515.02 −1.08%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Vertex Pharmaceuticals Inc / Ma since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

VRTXGlobal equities (VT)

$10,000 grew to $57,835. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −41.6% in 10/2021, measured from the peak in 07/2020. It took 25 months to get back to the old peak.

1-year return
+22.0%
5-year return p.a.
+23.0%
10-year return p.a.
+19.2%
Volatility p.a.
27.1%
Largest decline
−41.6%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue2,9122,7702,9653,0763,1902,9873,3343,441
Gross profit2,4892,4072,5572,6622,7242,5942,8452,915
Operating income1,0266301,1511,1861,2061,1381,247713
EBITDA1,0736791,2031,2401,2621,1941,303782
Net income9136461,0331,0831,1911,0311,100654
Earnings per share3.532.493.994.204.644.024.312.56
Balance sheet
Total assets22,53322,88124,03724,86225,64326,48427,42332,736
Liabilities6,1246,3846,8617,5446,9777,1237,17511,829
Equity16,41016,49617,17517,31918,66619,36220,24820,907
Cash4,5704,6754,9724,9405,0855,4936,1444,979
Long-term debt––––0.0––3,497
Cash flow
Operating cash flow5858191,0731,2414981,4281,125643
Capital expenditure-93-41-146-102-149-133-112-97
Free cash flow4927789271,1403491,2951,013546

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2017 at +103.4%, weakest 2021 at −7.1%. 7 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
3 Nov 2026$2.56
4 Aug 2026$4.31
5 May 2026$4.02
13 Feb 2026$4.64
4 Nov 2025$4.20
5 Aug 2025$3.99
6 May 2025$2.49
13 Feb 2025$3.53
5 Nov 2024$4.01
2 Aug 2024−$13.92
7 May 2024$4.21
15 Feb 2024$3.71

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€118bn
Market cap in trading currency
$131bn
Enterprise value
$129bn
P/E
33.2
P/S
10.08
P/B
6.25
EV/Sales
9.94
EV/EBITDA
28.4
Earnings yield
3.0%
FCF yield
2.5%

Results (last four quarters)

Revenue
$13.0bn
Gross profit
$11.1bn
EBITDA
$4.54bn
Net income
$3.98bn
Earnings per share
$15.53
Revenue per share
$51.08
Revenue growth
+11.8%
Earnings growth
−39.6%

Profitability

Gross margin
85.5%
Operating margin
33.2%
Net margin
30.7%
Return on equity
20.8%
Return on assets
12.1%

Balance sheet and cash flow

Cash
$6.30bn
Cash per share
$24.86
Financial debt
$4.50bn
Debt/equity %
22
Current ratio
2.34
Book value per share
$82.46
Operating cash flow
$3.69bn
Free cash flow
$3.20bn

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
0%
Ex-dividend date
–

Shares and trading

Shares outstanding
254m
Volume
1.71m
Avg. volume 3 months
1.24m
Relative volume
1.4

Price and technicals

Price
$515.02
1 day
−1.1%
52-week high
$558.88
52-week low
$422.32
Distance to 52-week high
−7.8%
Distance to 52-week low
+22.0%
Distance to 50-day line
−1.5%
Distance to 200-day line
+6.2%
RSI (14)
41
Volatility 1M
29.4%

Performance

1 week
−4.4%
1 month
−3.8%
3 months
−5.9%
6 months
+18.5%
YTD
+13.6%
1 year
+22.3%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has VRTX performed since 11/2016?

$10,000 grew to $57,835 by 20 Nov 2026, which is +19.2% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is VRTX?

Volatility was 27.1% per year, measured on monthly returns. The largest decline from a peak was −41.6%, with the low in 10/2021.

How does VRTX compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, VRTX returned +19.2% at 27.1%. The correlation of monthly returns was 0.28; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Vertex Pharmaceuticals Inc / Ma (VRTX): Return and risk